Eli Lilly and Co., of Indianapolis, and Sanford Burham Prebys Medical Discovery Institute in La Jolla, Calif., disclosed a three-year extension to their existing collaboration to discover and develop immunological therapies. The goals of the agreement are to advance ongoing projects, including a phase I trial of an immune therapy that arose from the research collaboration, and to expand the previous scope to include omics-based target identification studies. Researchers will use technologies, including CRISPR, to discover novel drug targets to treat autoimmune disorders.